Publications
Detailed Information
Recalcitrant Atopic Dermatitis Treated with Omalizumab
Cited 25 time in
Web of Science
Cited 32 time in Scopus
- Authors
- Issue Date
- 2010-08
- Publisher
- KOREAN DERMATOLOGICAL ASSOC
- Citation
- ANNALS OF DERMATOLOGY; Vol.22, no.3; 349-352
- Keywords
- Atopic dermatitis ; Biologies ; Omalizumab
- Abstract
- Atopic dermatitis (AD) is a chronic cutaneous inflammatory disease. Various categories of therapeutic medications are used for treating AD. Omalizumab is a monoclonal anti-IgE antibody that binds to IgE molecules at the high-affinity receptor (Fc epsilon RI) binding site. Therefore, omalizumab can be used as a potential new systemic treatment agent for recalcitrant AD patients with elevated IgE levels. A 34-year-old man had been treated for AD with several topical and oral agents. However, he was refractory to these therapies and his serum IgE levels were very high. We treated him with omalizumab. After 8 months of the treatment, his symptoms were notably improved and the SCORAD index was decreased. Thus, we report on the first case of recalcitrant AD that was successfully treated with omalizumab in Korea.
- ISSN
- 1013-9087
- Language
- English
- Files in This Item:
- Appears in Collections:
Item View & Download Count
Items in S-Space are protected by copyright, with all rights reserved, unless otherwise indicated.